Appointment dossier — Small Cell Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Small Cell Carcinoma
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT05768178 · Phase 2 / Phase 3 — DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (United Kingdom)
- NCT06172478 · Phase 2 — A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (United States)
- NCT07169994 · Phase 1 / Phase 2 — A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (China)
- NCT06781983 · Phase 1 — Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors (United States)
- NCT06270706 · Phase 1 — A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors (United States)
- NCT07161310 — Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors (Germany)
- NCT06627647 · Phase 3 — A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (United States)
- NCT06080776 · Phase 3 — SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations (China)
- NCT06623422 · Phase 3 — A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (United States)
- NCT07150663 · Phase 3 — Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (China)
- NCT05429463 · Phase 3 — Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） (China)
- NCT07070440 · Phase 1 / Phase 2 — DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) (China)
- NCT06465329 · Phase 2 — A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) (United States)
- NCT06205927 · Phase 2 — Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer (China)
- NCT07085182 · Phase 2 — Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study (China)
- NCT05254184 · Phase 1 — KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC (United States)
- NCT06473961 · Phase 1 — A Phase Ib Study of GC101 in NSCLC (China)
- NCT05403554 · Phase 1 — A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers (France)
Most-relevant first: trials that name Small Cell Carcinoma, then broader trials you may still qualify for. 1515 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT05768178), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?